Zometa trials

Participants were randomized to receive therapy with Zometa either up front or only after researchers detected bone loss. Findings support the conclusion that Zometa contributes to a reduction in the risk of recurrence. A month integrated analysis of the trial found that 3.

Data from the third clinical trial, a pilot study involving 45 women with early stage breast cancer, suggest that Zometa therapy decreases the prevalence of disseminated tumor cells in bone marrow. In women with early stage breast cancer, the presence of these cells in the bone marrow is associated with distant recurrence and death. The study is ongoing, and additional data are necessary to assess whether the results become statistically significant.

The need for treatments for bone disorders is growing as the population continues to age. Zometa was studied in combination with chemotherapy to treat breast cancer patients. Results of the study, announced in , showed zometa was not effective in preventing recurrence of tumours. The study was conducted on 3, breast cancer patients. The patent on zometa expires in and approval for this new indication would have extended the patent by another three years.

Product Description Bone resorption inhibitor. Current Indication Bone metastases. Development Status Approved in 95 countries.

Zoledronic acid is the active substance in Zometa. Cancer can metastasise and spread to various other parts of the body. Zometa helps in preventing bone complications in cancer patients. Scemblix asciminib for the Treatment of Chronic Myeloid Leukaemia.

Clinical Trials Arena Pipeline Moves Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Clinical Trials Arena Weekly Roundup Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday.

Zometa chemical name: zoledronic acid is used to strengthen bones in women diagnosed with metastatic breast cancer that has spread to the bones. Zometa also is used to lower the risk of a skeletal-related event. Aredia chemical name: pamidronate also is used to reduce bone complications and bone pain caused by metastatic breast cancer that has spread to the bones.

The research was published online on Jan. Hortobagyi also is a member of the Breastcancer. Zometa and Aredia are bisphosphonates. Bisphosphonates limit the activity of certain bone cells, called osteoclasts, which help cause bone weakening and breakdown. Research has shown that bisphosphonates can increase the risk of atypical femur fractures when taken for 5 years or longer.

The femur is the large leg bone that runs from your hip to your knee. An atypical fracture means that the bone is broken in an unusual spot. Still, atypical femur fractures are rare -- only about 0. Bisphosphonates also can sometimes cause another rare but serious side effect, osteonecrosis of the jaw, a condition in which the cells in the jawbone start to die.